90 related articles for article (PubMed ID: 23129735)
21. Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.
Georgin-Lavialle S; Lhermitte L; Suarez F; Yang Y; Letard S; Hanssens K; Feger F; Renand A; Brouze C; Canioni D; Asnafi V; Chandesris MO; Aouba A; Gineste P; Macintyre E; Mansfield CD; Moussy A; Lepelletier Y; Dubreuil P; Hermine O
Eur J Haematol; 2012 Jul; 89(1):47-52. PubMed ID: 22324351
[TBL] [Abstract][Full Text] [Related]
22. Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion.
Fischer M; Harvima IT; Carvalho RF; Möller C; Naukkarinen A; Enblad G; Nilsson G
J Clin Invest; 2006 Oct; 116(10):2748-56. PubMed ID: 16964309
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L).
Jordan JH; Walchshofer S; Jurecka W; Mosberger I; Sperr WR; Wolff K; Chott A; Bühring HJ; Lechner K; Horny HP; Valent P
Hum Pathol; 2001 May; 32(5):545-52. PubMed ID: 11381374
[TBL] [Abstract][Full Text] [Related]
24. Aggressive systemic mastocytosis mimicking sclerosing cholangitis.
Marbello L; Anghilieri M; Nosari A; Minola E; Cairoli R; Ricci F; Morra E
Haematologica; 2004 Sep; 89(9):ECR35. PubMed ID: 15377487
[TBL] [Abstract][Full Text] [Related]
25. Transient production of stem cell factor in dermal cells but increasing expression of Kit receptor in mast cells during normal wound healing.
Huttunen M; Naukkarinen A; Horsmanheimo M; Harvima IT
Arch Dermatol Res; 2002 Oct; 294(7):324-30. PubMed ID: 12373338
[TBL] [Abstract][Full Text] [Related]
26. Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors.
Pryer NK; Lee LB; Zadovaskaya R; Yu X; Sukbuntherng J; Cherrington JM; London CA
Clin Cancer Res; 2003 Nov; 9(15):5729-34. PubMed ID: 14654558
[TBL] [Abstract][Full Text] [Related]
27. Simultaneous histochemical and immunohistochemical staining as a simple tool to identify mast cells within CD117-positive cell populations.
Ressel L; Ricci E; Bonassi P; Parolini O
Histopathology; 2012 Mar; 60(4):655-7. PubMed ID: 22260311
[No Abstract] [Full Text] [Related]
28. Regulation of mast cell characteristics by cytokines: divergent effects of interleukin-4 on immature mast cell lines versus mature human skin mast cells.
Thienemann F; Henz BM; Babina M
Arch Dermatol Res; 2004 Aug; 296(3):134-8. PubMed ID: 15322832
[TBL] [Abstract][Full Text] [Related]
29. Activity of triptolide against human mast cells harboring the kinase domain mutant KIT.
Jin Y; Chen Q; Shi X; Lu Z; Cheng C; Lai Y; Zheng Q; Pan J
Cancer Sci; 2009 Jul; 100(7):1335-43. PubMed ID: 19383029
[TBL] [Abstract][Full Text] [Related]
30. Temporary response of localized intracranial mast cell sarcoma to combination chemotherapy.
Guenther PP; Huebner A; Sobottka SB; Neumeister V; Weissbach G; Todt H; Parwaresch R
J Pediatr Hematol Oncol; 2001 Feb; 23(2):134-8. PubMed ID: 11216707
[TBL] [Abstract][Full Text] [Related]
31. In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V.
Böhm A; Sonneck K; Gleixner KV; Schuch K; Pickl WF; Blatt K; Peter B; Herrmann H; Schernthaner GH; Pehamberger H; Rabitsch W; Sperr WR; Valent P
Exp Hematol; 2010 Sep; 38(9):744-55. PubMed ID: 20553795
[TBL] [Abstract][Full Text] [Related]
32. Expression of the c-kit gene product in normal and neoplastic mast cells but not in neoplastic basophil/mast cell precursors from chronic myelogenous leukaemia.
Fukuda T; Kamishima T; Tsuura Y; Suzuki T; Kakihara T; Naito M; Kishi K; Matsumoto K; Shibata A; Seito T
J Pathol; 1995 Oct; 177(2):139-46. PubMed ID: 7490680
[TBL] [Abstract][Full Text] [Related]
33. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm.
Longley BJ; Tyrrell L; Lu SZ; Ma YS; Langley K; Ding TG; Duffy T; Jacobs P; Tang LH; Modlin I
Nat Genet; 1996 Mar; 12(3):312-4. PubMed ID: 8589724
[TBL] [Abstract][Full Text] [Related]
34. What is your diagnosis? Mast cell sarcoma.
Dunn K
J Small Anim Pract; 1997 Mar; 38(3):93, 108. PubMed ID: 9097238
[No Abstract] [Full Text] [Related]
35. KIT and mastocytosis.
Lim KH; Pardanani A; Tefferi A
Acta Haematol; 2008; 119(4):194-8. PubMed ID: 18566536
[TBL] [Abstract][Full Text] [Related]
36. Lamina propria c-kit+ immune precursors reside in human adult intestine and differentiate into natural killer cells.
Chinen H; Matsuoka K; Sato T; Kamada N; Okamoto S; Hisamatsu T; Kobayashi T; Hasegawa H; Sugita A; Kinjo F; Fujita J; Hibi T
Gastroenterology; 2007 Aug; 133(2):559-73. PubMed ID: 17681176
[TBL] [Abstract][Full Text] [Related]
37. Tumor-intrinsic and -extrinsic roles of c-Kit: mast cells as the primary off-target of tyrosine kinase inhibitors.
Pittoni P; Piconese S; Tripodo C; Colombo MP
Oncogene; 2011 Feb; 30(7):757-69. PubMed ID: 21057534
[TBL] [Abstract][Full Text] [Related]
38. Immunoreactivity for CD25 in gastrointestinal mucosal mast cells is specific for systemic mastocytosis.
Hahn HP; Hornick JL
Am J Surg Pathol; 2007 Nov; 31(11):1669-76. PubMed ID: 18059223
[TBL] [Abstract][Full Text] [Related]
39. Cell type-specific deficiency of c-kit gene expression in mutant mice of mi/mi genotype.
Isozaki K; Tsujimura T; Nomura S; Morii E; Koshimizu U; Nishimune Y; Kitamura Y
Am J Pathol; 1994 Oct; 145(4):827-36. PubMed ID: 7524330
[TBL] [Abstract][Full Text] [Related]
40. Targeting c-kit in the therapy of mast cell disorders: current update.
El-Agamy DS
Eur J Pharmacol; 2012 Sep; 690(1-3):1-3. PubMed ID: 22789565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
